|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNN |
Gene summary for SNN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNN | Gene ID | 8303 |
| Gene name | stannin | |
| Gene Alias | SNN | |
| Cytomap | 16p13.13 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | O75324 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8303 | SNN | P28T-E | Human | Esophagus | ESCC | 4.66e-19 | 2.17e-01 | 0.1149 |
| 8303 | SNN | P30T-E | Human | Esophagus | ESCC | 1.65e-15 | 5.01e-01 | 0.137 |
| 8303 | SNN | P31T-E | Human | Esophagus | ESCC | 1.88e-14 | 1.30e-01 | 0.1251 |
| 8303 | SNN | P32T-E | Human | Esophagus | ESCC | 3.48e-13 | 4.65e-02 | 0.1666 |
| 8303 | SNN | P36T-E | Human | Esophagus | ESCC | 2.95e-10 | 2.42e-01 | 0.1187 |
| 8303 | SNN | P37T-E | Human | Esophagus | ESCC | 1.52e-09 | 8.05e-02 | 0.1371 |
| 8303 | SNN | P39T-E | Human | Esophagus | ESCC | 3.21e-08 | 4.82e-02 | 0.0894 |
| 8303 | SNN | P42T-E | Human | Esophagus | ESCC | 2.05e-06 | 1.66e-01 | 0.1175 |
| 8303 | SNN | P47T-E | Human | Esophagus | ESCC | 2.59e-10 | 9.73e-02 | 0.1067 |
| 8303 | SNN | P48T-E | Human | Esophagus | ESCC | 2.85e-10 | 6.91e-02 | 0.0959 |
| 8303 | SNN | P49T-E | Human | Esophagus | ESCC | 2.59e-09 | 6.53e-01 | 0.1768 |
| 8303 | SNN | P52T-E | Human | Esophagus | ESCC | 4.72e-14 | 3.37e-01 | 0.1555 |
| 8303 | SNN | P54T-E | Human | Esophagus | ESCC | 1.47e-02 | 1.02e-01 | 0.0975 |
| 8303 | SNN | P56T-E | Human | Esophagus | ESCC | 1.67e-02 | 4.98e-01 | 0.1613 |
| 8303 | SNN | P57T-E | Human | Esophagus | ESCC | 2.05e-09 | 1.39e-01 | 0.0926 |
| 8303 | SNN | P61T-E | Human | Esophagus | ESCC | 1.27e-05 | 1.43e-01 | 0.099 |
| 8303 | SNN | P62T-E | Human | Esophagus | ESCC | 2.12e-09 | 1.48e-01 | 0.1302 |
| 8303 | SNN | P65T-E | Human | Esophagus | ESCC | 1.87e-08 | 1.49e-01 | 0.0978 |
| 8303 | SNN | P74T-E | Human | Esophagus | ESCC | 6.83e-03 | 7.09e-02 | 0.1479 |
| 8303 | SNN | P75T-E | Human | Esophagus | ESCC | 6.71e-16 | 1.54e-01 | 0.1125 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
| GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNN | SNV | Missense_Mutation | c.126N>G | p.Ser42Arg | p.S42R | O75324 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.928) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SNN | SNV | Missense_Mutation | c.21N>A | p.Ser7Arg | p.S7R | O75324 | protein_coding | deleterious_low_confidence(0) | benign(0.037) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNN | insertion | Frame_Shift_Ins | novel | c.170_171insCTTGGCACCTGGTTGCTGTGTTCCTGACAAT | p.Lys57AsnfsTer72 | p.K57Nfs*72 | O75324 | protein_coding | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR | ||
| SNN | SNV | Missense_Mutation | rs747411695 | c.119N>A | p.Arg40His | p.R40H | O75324 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| SNN | SNV | Missense_Mutation | novel | c.141N>T | p.Glu47Asp | p.E47D | O75324 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.874) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SNN | SNV | Missense_Mutation | c.191N>G | p.Gln64Arg | p.Q64R | O75324 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.728) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
| SNN | SNV | Missense_Mutation | rs775385437 | c.67N>A | p.Ala23Thr | p.A23T | O75324 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.948) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| SNN | SNV | Missense_Mutation | c.50N>C | p.Val17Ala | p.V17A | O75324 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.822) | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNN | SNV | Missense_Mutation | c.110N>A | p.Arg37Gln | p.R37Q | O75324 | protein_coding | deleterious_low_confidence(0.03) | benign(0.247) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
| SNN | SNV | Missense_Mutation | c.118N>T | p.Arg40Cys | p.R40C | O75324 | protein_coding | deleterious_low_confidence(0) | benign(0.092) | TCGA-HU-A4GQ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |